Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer

Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer

PURPOSE:To prospectively investigate whether Lipiodol can be used as a potential imaging biomarker of tumor response after conventional transarterial chemoembolization (cTACE) for both primary and secondary liver cancer. MATERIALS AND METHODS: This prospective single-center single-arm clinical trial...

Full description

Bibliographic Details
Main Authors: Milena A. Miszczuk, Julius Chapiro, Jean-Francois H. Geschwind, Vinayak Thakur, Nariman Nezami, Fabian Laage-Gaupp, Michal Kulon, Johanna M.M. van Breugel, Arash Fereydooni, MingDe Lin, Lynn Jeanette Savic, Bruno Tegel, Tamara Wahlin, Eliot Funai, Todd Schlachter
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319304346

Internet

http://www.sciencedirect.com/science/article/pii/S1936523319304346

Similar Items